Suven Life Sciences gets patents for neurological drug
Suven Life Sciences gets patents for neurological drug
Related Articles
-
Comparing first level patent data with value-added patent information: A case study in the pharmaceutical field q
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0172219008000823-mainDownload
-
Priority setting for orphan drugs: An international comparison
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0168851010002691-mainDownload
-
First Look At False Marking Under The AIA – Courtesy (Pharma Patents)
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 14 MAY 2015POSTED IN FEDERAL CIRCUIT DECISIONSIn Sukumar v. Nautilus, Inc., the Federal Circuit took its first...
-
Orphan drug market to reach $176bn by 2020 – Courtesy ( PMLiVe)
Pharma Live, , Intellectual Property Rights, 0
pharmacistThe global orphan drug market is expected to account for 19% of all branded prescription drug sales by 2020,...
-
Drug patents are Bad for your health: the cost of mismarketing – By Dean Baker
Pharma Live, , Intellectual Property Rights, 0
The rationale for granting patents for new drugs is to give companies incentives to research new and better drugs....
-
The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0167629610001219-mainDownload
-
The relationship between a firm’s patent quality and its market value — The case of US pharmaceutical industry
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0040162509000791-mainDownload
-
Telmisartan: no double-dipping says CJEU, as it avoids answering all the questions – Courtesy (The SPC Blog)
Pharma Live, , Intellectual Property Rights, 0
The Court of Justice of the European Union (CJEU) delivered its ruling in Case C‑577/13, Actavis Group PTC EHF, Actavis UK...